Author/Authors :
Akhlaghi، Arash نويسنده MD, Fellowship of Cardiology, Department of Cardiology, Isfahan Cardiovascular Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. , , Shirani، Shahin نويسنده Associate Professor, Hypertension Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran , , Ziaie، Naghmeh نويسنده MD, Cardiologist, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. , , PIRHAJI، OMID نويسنده Isfahan Medical Students’ Research Center, Isfahan University of Medical Sciences, Isfahan, Iran , , Yaran، Majid نويسنده Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran , , Shahverdi، Golnoosh نويسنده Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. , , Sarrafzadegan، Nizal نويسنده MD, Professor of Cardiology, Isfahan Cardiovascular Research Center, IUMS, Isfahan , , KHOSRAVI، ALIREZA نويسنده , , KHOSRAVI، ELHAM نويسنده ,
Abstract :
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD). The CYP2C19*2 is the most important allele responsible for resistance to clopidogrel therapy. This study examined CYP2C19 gene polymorphism (CYP2C19*1 and *2) in Iranian patients.
METHODS: This cross-sectional study was performed on 43 Iranian patients with CAD who underwent percutaneous coronary intervention (PCI) and received drug-eluted stents (DES). CYP2C19 polymorphisms were assessed using real time PCR and frequency of CYP2C19*1 and CYP2C19*2 were determined, and then homo- or heterozygous state of genes was detected by Melt Curve Analysis method.
RESULTS: Forty three patients (mean age = 58.8 ± 10.0 years, 79.1% male) participated in this study. CYP2C19*1/CYP2C19*1 genotype was observed in 31 (72.1%) of participates, CYP2C19*1/CYP2C19*2 genotype in 10 (23.3%), and CYP2C19*2/CYP2C19*2 genotype in 2 patients (4.7%). The frequency of CYP2C19*2 allele in the sample was 27.9%.
CONCLUSION: This study demonstrated a high prevalence of CYP2C19*2 gene polymorphism in Iranian patients. Further studies with larger samples or longitudinal are required to determine the effects of this polymorphism on the prognosis of CAD patients in our population.
